MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Home・Akcijų sąrašas・Champions Oncology Inc

C
Champions Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.67 -1.22

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.63

Max

5.8100000000000005

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-514K -278K
Pardavimai	1.5M 17M
P/E Sektoriaus vid.	35.118 66.418
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-1.679
Darbuotojai	213
EBITDA	-458K 154K

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.1M 82M
Ankstesnė atidarymo kaina	6.89
Ankstesnė uždarymo kaina	5.67

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

5.77 / 7.61 Palaikymas ir pasipriešinimas

Champions Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-14 23:36; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026-04-14 23:24; UTC

Karštos akcijos

Stocks to Watch: Gloo, Broadcom, GitLab

2026-04-14 22:42; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026-04-14 21:32; UTC

Pagrindinės rinkos jėgos

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026-04-14 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026-04-14 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-04-14 22:54; UTC

Uždarbis

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026-04-14 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026-04-14 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026-04-14 22:14; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026-04-14 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026-04-14 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026-04-14 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-04-14 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 20:32; UTC

Karštos akcijos

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026-04-14 19:59; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026-04-14 19:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-14 19:09; UTC

Įsigijimai, susijungimai, perėmimai

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026-04-14 18:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-14 18:30; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Champions Oncology Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Champions Oncology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

5.77 / 7.61Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.